PT2044079E - Derivados de camptotecina com atividade antitumoral - Google Patents

Derivados de camptotecina com atividade antitumoral Download PDF

Info

Publication number
PT2044079E
PT2044079E PT77860633T PT07786063T PT2044079E PT 2044079 E PT2044079 E PT 2044079E PT 77860633 T PT77860633 T PT 77860633T PT 07786063 T PT07786063 T PT 07786063T PT 2044079 E PT2044079 E PT 2044079E
Authority
PT
Portugal
Prior art keywords
antitumor activity
camptothecin derivatives
camptothecin
derivatives
antitumor
Prior art date
Application number
PT77860633T
Other languages
English (en)
Portuguese (pt)
Inventor
Fontana Gabriele
Bombardelli Ezio
Samori Cristian
Battaglia Arturo
Manzotti Carla
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of PT2044079E publication Critical patent/PT2044079E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
PT77860633T 2006-07-26 2007-07-13 Derivados de camptotecina com atividade antitumoral PT2044079E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001473A ITMI20061473A1 (it) 2006-07-26 2006-07-26 Derivati della camptotecina ad attivita antitumorale

Publications (1)

Publication Number Publication Date
PT2044079E true PT2044079E (pt) 2016-03-09

Family

ID=38668829

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77860633T PT2044079E (pt) 2006-07-26 2007-07-13 Derivados de camptotecina com atividade antitumoral

Country Status (20)

Country Link
US (1) US8217053B2 (enExample)
EP (1) EP2044079B1 (enExample)
JP (1) JP5313894B2 (enExample)
KR (1) KR101412157B1 (enExample)
CN (1) CN101495486B (enExample)
AU (1) AU2007278500B2 (enExample)
BR (1) BRPI0714553B8 (enExample)
CA (1) CA2658900C (enExample)
DK (1) DK2044079T3 (enExample)
ES (1) ES2561356T3 (enExample)
HU (1) HUE027890T2 (enExample)
IL (1) IL196653A (enExample)
IT (1) ITMI20061473A1 (enExample)
MX (1) MX2009000827A (enExample)
NO (1) NO341812B1 (enExample)
PL (1) PL2044079T3 (enExample)
PT (1) PT2044079E (enExample)
RU (1) RU2450008C2 (enExample)
SI (1) SI2044079T1 (enExample)
WO (1) WO2008011994A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195288B2 (en) * 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
KR101586030B1 (ko) * 2014-01-22 2016-01-15 주식회사 엘지생활건강 캄프토테신을 유효성분으로 포함하는 체모 성장 억제용 조성물
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
EP3831853A4 (en) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
IL325918A (en) 2018-07-31 2026-03-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates for use in the treatment of metastatic brain tumor
US10568873B1 (en) * 2019-02-14 2020-02-25 United Arab Emirates University Safranal-sorafenib combination therapy for liver cancer
CN112225745B (zh) * 2020-11-16 2021-10-12 烟台大学 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药(杭州)有限公司 适用于抗体-药物偶联物的毒素分子
WO2022262789A1 (zh) * 2021-06-17 2022-12-22 明慧医药(杭州)有限公司 一种抗肿瘤化合物及其应用
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药(杭州)有限公司 适用于抗体-药物偶联物的毒素分子
WO2024230752A1 (zh) * 2023-05-08 2024-11-14 甘李药业股份有限公司 喜树碱衍生物、接头、配体-药物偶联物及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US5972955A (en) 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
FR2757515B1 (fr) * 1996-12-20 2000-05-05 Sod Conseils Rech Applic Formes prodrogues et nouveaux analogues de la camptothecine, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6881555B2 (en) * 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
DE60209517D1 (de) * 2001-09-25 2006-04-27 Reddys Lab Ltd Dr Pharmazeutisch geeignete salze von 20(s)-camptothecinen
US20060084167A1 (en) * 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells

Also Published As

Publication number Publication date
NO341812B1 (no) 2018-01-29
CA2658900A1 (en) 2008-01-31
RU2009102243A (ru) 2010-07-27
EP2044079B1 (en) 2015-12-09
ITMI20061473A1 (it) 2008-01-27
AU2007278500A2 (en) 2010-09-09
AU2007278500A1 (en) 2008-01-31
IL196653A0 (en) 2009-11-18
PL2044079T3 (pl) 2016-06-30
AU2007278500B2 (en) 2012-06-07
HK1135691A1 (en) 2010-06-11
WO2008011994A1 (en) 2008-01-31
CN101495486B (zh) 2013-05-15
CN101495486A (zh) 2009-07-29
HUE027890T2 (en) 2016-11-28
ES2561356T3 (es) 2016-02-25
CA2658900C (en) 2015-09-15
DK2044079T3 (en) 2016-02-29
US20100120816A1 (en) 2010-05-13
IL196653A (en) 2015-04-30
NO20090251L (no) 2009-01-16
KR20090033456A (ko) 2009-04-03
MX2009000827A (es) 2009-02-03
JP2009544634A (ja) 2009-12-17
BRPI0714553B1 (pt) 2020-11-17
JP5313894B2 (ja) 2013-10-09
RU2450008C2 (ru) 2012-05-10
US8217053B2 (en) 2012-07-10
BRPI0714553A2 (pt) 2013-03-26
KR101412157B1 (ko) 2014-06-25
BRPI0714553B8 (pt) 2021-05-25
EP2044079A1 (en) 2009-04-08
SI2044079T1 (sl) 2016-02-29

Similar Documents

Publication Publication Date Title
IL196653A0 (en) Camptothecin derivatives with antitumor activity
IL193175A0 (en) Pyridine-2-carboxamide derivatives
IL194367A0 (en) Dihydropyrazolopyrimidinone derivatives
IL196543A0 (en) Pyridizinone derivatives
IL193641A0 (en) Spiroindolinone derivatives
IL195013A0 (en) Pyridopyrimidinone derivatives
IL198319A0 (en) Spiroindolinone derivatives
IL195422A0 (en) 2-pyrazinecarboxamide derivatives
IL192401A0 (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives
IL196364A0 (en) Aminoindazolylurea derivatives
IL198059A0 (en) 2-aminocarbonyl-pyridine derivatives
IL193211A0 (en) Indazole-heteroaryl derivatives
IL198645A0 (en) 5-hydroxymethyl-oxazolidin-2-one derivatives
ZA200903175B (en) Spiro-piperidine derivatives
IL197152A0 (en) 5-phenyl-nicotinamide derivatives
ZA200901034B (en) Avermectin derivatives
ZA201007615B (en) Aminopyridine derivatives
GB0625842D0 (en) Indolizine derivatives
IL196652A0 (en) Camptothecin derivatives with antitumor activity
TWI339663B (en) Spiro-piperidine derivatives
ZA200807460B (en) Spiroindolinone derivatives
IL184113A0 (en) Indole derivatives with antitumor activity
IL197239A0 (en) Phenyloxyaniline derivatives
ZA200805910B (en) Taxol derivatives with antitumor activity
GB2440643B (en) Antitumor combinations comprising taxane derivatives